Checkmate Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Checkmate Pharmaceuticals Inc (CMPI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Checkmate Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Checkmate Pharmaceuticals Inc | - | - | - | Yes |
| Competitors combined (1) | - | |||
| High-Confidence Competitors (42) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CMPI Stock Performance relative to its Competitors
CMPI Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Northwest Biotherapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Checkmate Pharmaceuticals Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Checkmate Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Checkmate Pharmaceuticals Inc |
227.12 | - |
 Northwest Biotherapeutics Inc |
274.45 | 2.17 |
| SUBTOTAL | 501.57 | 2.17 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Checkmate Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Checkmate Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Checkmate Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Allarity Therapeutics Inc | Company report | 85% |
| Omniab Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Kodiak Sciences Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Keros Therapeutics Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Adverum Biotechnologies Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Zai Lab Limited | Company report | 85% |
| INVO | Company report | 85% |
| Oculis Holding Ag | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Alimera Sciences Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Unity Biotechnology Inc | Company report | 85% |
| Eyepoint Inc | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| 4d Molecular Therapeutics Inc | Company report | 85% |
| Kalvista Pharmaceuticals Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Biocon Biologics Ltd | Company report | 85% |
| Our Marketed Products | Company report | 85% |
| FENCF | Company report | 85% |
| Arcutis Biotherapeutics Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Canton Strategic Holdings Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Fennec Pharmaceuticals Inc | Company report | 85% |
| Vir Biotechnology Inc | Company report | 85% |
| Otonomy Inc | Company report | 85% |
| Ocular Therapeutix Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Viking Therapeutics Inc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Revance Therapeutics Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Blueprint Medicines Corporation | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Intercept Pharmaceuticals inc | Company report | 85% |
| Apellis Pharmaceuticals Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Northwest Biotherapeutics Inc | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Cymabay Therapeutics Inc | Company report | 85% |
| Karyopharm Therapeutics Inc | Company report | 85% |
| Argenx Se | Company report | 85% |
| Sanofi | Company report | 85% |
| Travere Therapeutics Inc | Company report | 85% |
| Neurogene Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Madrigal Pharmaceuticals Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Rocket Pharmaceuticals Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Checkmate Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Checkmate Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Checkmate Pharmaceuticals Inc | 227 | - | - |
| Northwest Biotherapeutics Inc | 274 | 20,695 | -370,324 |
| PEERS TOTAL | 274 | 20,695 | -370,324 |
Checkmate Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.6x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 0.8x | 5.3x | -4.5x |
| Return on Equity | -83.92 % | industry aggregate | -108.25 % |
| Return on Invested Capital | -41.98 % | -10.86 % (avg) | -31.12 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Checkmate Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 108.3 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-25.8% annualized).
Methodology: see Methodology: SWOT Analysis.
Checkmate Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Checkmate Pharmaceuticals Inc | 5.77 | 8.81 | - |
| Northwest Biotherapeutics Inc | 0.03 | 0.06 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Checkmate Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Checkmate Pharmaceuticals Inc | Q1 2022 | - | - |
| Northwest Biotherapeutics Inc | Q2 2026 | +516.0 % | - |
| PEERS TOTAL | +516.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Checkmate Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Checkmate Pharmaceuticals Inc | Q1 2022 | - | - |
| Northwest Biotherapeutics Inc | Q2 2026 | - | -34.9 % |
Checkmate Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Checkmate Pharmaceuticals Inc | - | - | - |
| Northwest Biotherapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Checkmate Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Checkmate Pharmaceuticals Inc | - | - |
| Northwest Biotherapeutics Inc | - | 126.30 |
| PEERS AVERAGE | - | 230.82 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.